Regulora is a PDT that is accessed through a smartphone app. It consists of seven therapy sessions provided over three months, with practice sessions between. Regulora is delivers Gut-Directed Hypnotherapy (GDH) and includes the collection of adherence data and patient reported outcomes using clinically-validated survey instruments. Unlike most digital therapeutics that focus on behavioral health issues, Regulora treats abdominal pain, a somatic symptom that is the chief IBS complaint. For decades, in-person psychological interventions have been effective in treating IBS but were accessible to very few patients.

Regulora provides broad access to this treatment through a mechanism familiar to both patients and doctors: obtaining a prescription. By providing physicians an easy way to prescribe treatment and patients a convenient way to undergo therapy privately at home, Regulora offers a non-drug option that addresses the stigma often associated with bowel problems and psychological interventions.

metaMe Health is a pioneer in developing Prescription Digital Therapeutics (PDTs). In 2022, our work was recognized by being included on the “50 on Fire” list of up-and-coming Chicago companies, being named one of the Top 150 most promising Digital Health Companies of 2022 nationwide by CBInsights, and being selected as a finalist in the LyfeBulb-Bristol Myers Squibb Inflammatory Bowel Disease Challenge. In 2021, our lead product Regulora® became the first FDA-cleared PDT specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults. More than 30 million Americans are affected by IBS, and the abdominal pain, diarrhea, and/or constipation that comes with it. Regulora provides relief by digitizing a standardized Brain-Gut therapy approach that has been clinically proven to be effective in reducing IBS symptoms.

Significantly reduce unnecessary hospital readmissions up to 85% with this product proven across many health conditions including congestive heart failure, atrial fibrillation, COPD and spinal fusion surgery. Trigger multiple waves of psychographic segmented patient communications over 30, 90, 120+ days post-discharge to share the most relevant and timely information on their condition and care. Monitor patient response and recovery on an intuitive dashboard and trigger tasks for care team to follow-up in case a patient is at risk for readmission.

PatientBond’s cloud-based, digital health platform automates patient engagement and care coordination with two-way communications, response tracking and real-time adjustment & optimization. PatientBond offers solutions to tackle many business and clinical challenges, including Healthcare Consumer Awareness/Marketing, Pre Visit, Point of Care, Patient Loyalty and Patient Collections for Health Systems, Physician Practices, Urgent Care Centers and Payers. PatientBond personalizes communications based on patients’ motivations and channel preferences using a proprietary psychographic segmentation model developed by healthcare consumer experts from P&G, the worldwide leader in consumer products and advertising. PatientBond enables you to activate desired patient behaviors to increase revenue and volume while ensuring cost avoidance and savings.

Non-drug therapy with no side effects

This automates the post-discharge patient follow-up and monitoring process, saving extensive staff time and effort. Psychographic messaging motivates patients to pursue the behaviors necessary for a healthy recovery.

Psychographic messaging motivates patients to pursue the behaviors necessary for a healthy recovery. PatientBond has reduced all-cause readmissions by up to 85% across challenging conditions such as congestive heart failure, atrial fibrillation and COPD.